|
1
|
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
|
J Clin Oncol
|
2005
|
1.87
|
|
2
|
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
|
J Clin Oncol
|
2006
|
1.45
|
|
3
|
Immunologic treatments for precancerous lesions and uterine cervical cancer.
|
J Exp Clin Cancer Res
|
2014
|
0.96
|
|
4
|
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
|
J Clin Oncol
|
2003
|
0.93
|
|
5
|
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.
|
Breast Cancer Res Treat
|
2014
|
0.88
|
|
6
|
Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials.
|
PLoS One
|
2013
|
0.87
|
|
7
|
A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines.
|
Oncology
|
2008
|
0.85
|
|
8
|
Increasing single epirubicin doses in advanced soft tissue sarcomas.
|
J Clin Oncol
|
2002
|
0.84
|
|
9
|
Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations.
|
Breast Cancer Res Treat
|
2014
|
0.84
|
|
10
|
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.
|
J Exp Clin Cancer Res
|
2011
|
0.83
|
|
11
|
Cancer stem cells: are they responsible for treatment failure?
|
Future Oncol
|
2014
|
0.83
|
|
12
|
Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer.
|
J Cell Physiol
|
2015
|
0.81
|
|
13
|
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.
|
J Exp Clin Cancer Res
|
2013
|
0.79
|
|
14
|
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
|
J Exp Clin Cancer Res
|
2013
|
0.78
|
|
15
|
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines.
|
Cancer Chemother Pharmacol
|
2010
|
0.77
|
|
16
|
Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer.
|
Anticancer Res
|
2005
|
0.76
|
|
17
|
Hot flushes in women with breast cancer: state of the art and future perspectives.
|
Expert Rev Anticancer Ther
|
2013
|
0.75
|
|
18
|
Parametric control of thermal self-pulsation in micro-cavities.
|
Opt Lett
|
2017
|
0.75
|